Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Genentech, a member ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...

These studies evaluate the efficacy of evorpacept in combination with pembrolizumab and chemotherapy in frontline head and neck squamous cell carcinoma (HNSCC), with a focus on achieving superior ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2 ... rates and outcomes. The results from DESTINY-Breast06 [NCT04494425] show that Enhertu has the ...

Camizestrant significantly improved progression-free survival (PFS) compared to fulvestrant in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer ... The objective response ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...